The "avoid institutional stocks" strategy may only have six months left: CITIC judges that large-cap stocks will outperform small caps next year, with early 2027 being the window to position
It is expected that during this round of adjustment, institutional large-cap stocks will be cleared out much faster than in the past, while the slow clearing process for micro- and small-cap stocks may have only just begun.
CITIC SEC released a research report stating that the adjustment speed of institutional large-cap stocks in this round is likely to be far faster than in the past, and the speed of chip clearing will also be far faster than in the past. Therefore, the market's liquidity "blood loss" will not be as prolonged as before, but may instead be short, sharp, and quick. Starting in early 2027, as the new assessment year restarts, if a final round of clearing occurs, investors can consider positioning based on relative fundamental strength logic rather than continuing to cling to chip-flow logic. It is expected that during this adjustment, institutional large-cap stocks will clear far faster than in the past, while the slow clearing process for micro- and small-cap stocks may have only just begun.
CITIC SEC's main views are as follows:
New issuance of active equity funds vs. increased subscriptions to certain existing products
1) There is a huge difference between new issuance and subscription/redemption structure. Near the market highs in 2015 and 2021, equity-biased funds both experienced a round of concentrated issuance. In 2015Q2 and 2021Q1, new issuance of equity-biased funds reached RMB318.6 billion and RMB564.5 billion, respectively. In this round, the quarter with the most issuance, 2026Q1, saw only RMB105.1 billion, falling to RMB81.2 billion in Q2. Even spreading out the issuance peak, average quarterly new issuance from 2025Q3 to 2026Q2 was RMB76 billion, only 23% of the quarterly average of RMB325.3 billion from 2020 to 2021. Therefore, compared with the previous round, funds entering at high levels through new funds have clearly decreased.
It is worth noting that in 2021Q1, existing equity-biased funds as a whole still had net inflows of RMB29.2 billion. In the quarter of this round's peak (2026Q2), they already had net outflows of RMB189.9 billion. After the market adjustment in Q3, net outflows actually narrowed to RMB117.6 billion. In this round, net subscriptions to existing equity-biased funds are concentrated in a small number of products, with technology being the most important direction. From 2025Q3 to 2026Q2, only 25.3% of products received net subscriptions, and these products together saw net inflows of RMB807.7 billion, with the top 50 products by net subscription amount accounting for 45.5%.
2) The expansion of "fixed income plus" products has similarities to the expansion of IPO subscription funds in 2015. CITIC SEC estimates that since 2025Q1, public fixed income plus products have received net subscriptions for seven consecutive quarters, with net subscriptions of RMB309.0 billion, RMB186.6 billion, and RMB63.1 billion in the first three quarters of this year, respectively. Among all A-share holdings disclosed in this year's interim reports, TMT holdings accounted for 44.2% in total, equivalent to 5.2% of fixed income plus fund net assets. Under the top-holdings basis, the TMT share of sample fixed income plus funds rose from 22.0% at the end of Q1 to 53.6% at the end of Q2, then fell back to 42.7% at the end of Q3, still clearly higher than TMT's 25.9% share of total A-share free-float market capitalization in the same period. Even among fixed income plus products with relatively low overall equity exposure, subscription funds were more biased toward products whose equity holdings were concentrated in technology. Nominally fixed income, such products nevertheless temporarily achieved excess returns clearly surpassing those of fixed income products by increasing technology stock holdings. This situation is somewhat similar to the state of IPO subscription funds during the most frenzied phase of the 2015 bull market.
When the stock market is doing well, IPO subscription returns look like risk-free high fixed income. Once the market turns downward, the return characteristics of the products instantly collapse. After new share issuance was suspended in early July 2015 (combined with the market decline), CITIC SEC estimates that IPO subscription funds concentratedly established in Q2 saw single-quarter net redemptions of RMB717.8 billion. Taking five low-position products with relatively large share shrinkage at the time as an example, by the end of September 2015, the combined shares of the five funds had fallen from 66.95 billion shares to 5.05 billion shares, a decrease of 92.5%. Two of the funds explicitly mentioned in their Q3 reports that they had reduced equity positions and shifted funds into short-duration, more liquid fixed income instruments. Fixed income plus products are similar to IPO subscription funds: their true risk-return characteristics are easily obscured by market conditions, and under the "horse-racing mechanism," low equity positions likewise obscure true volatility risk.
Track and "fixed income plus" subscriptions as the main incremental source vs. new fund issuance as the main incremental source
Subscriptions to existing products, especially subscriptions to track-style funds, are more like chasing gains during a rally and react faster to market trends and changes in subscriptions and redemptions. New fund issuance, by contrast, is more like channel-driven wealth management behavior, often showing "holding on" or even contrarian adding during the early decline, and gradually exiting as net asset values recover. For example, in 2022Q1, the vast majority of active equity products saw contrarian net subscriptions, buying the dip as prices fell. In 2026Q3, except for healthcare track funds, other track products all showed net redemptions.
In violent market fluctuations, the behavioral patterns of holders of new and old funds also differ greatly. Looking back at the period when the bull market accelerated toward its peak in 2015Q2, funds established in 2005 and earlier had a net redemption rate of 39.0% that quarter, funds established from 2006 to 2008 had a net redemption rate as high as 33.6%, funds established from 2009 to 2013 had a net redemption rate of only 7.3%, while new funds established from 2014 to 2015 actually had net subscriptions of 7.0% that quarter.
It can thus be seen that whether new fund issuance or subscriptions to existing products constitute the incremental source during the acceleration phase of a bull market has a major impact on the clearing process after the market turns downward. The former clears slowly, while the latter clears quickly, and this round clearly belongs to the latter. The expansion of fixed income plus products will accelerate the clearing process, just like IPO subscription funds in 2015: once market conditions change, stop-loss and repositioning actions will be very decisive. This means that during this market adjustment, institutional large-cap stocks may clear noticeably faster than in the past. The Fund Heavy Holdings 100 Index has already retraced 38.9% since June 30 this year, and the pace of decline has exceeded the first wave of adjustment after market peaks in 2007, 2015, and 2021.
Inflows from low-risk-appetite absolute-return funds vs. large inflows from fund investors and retail investors
The incremental funds in this round mainly came from absolute-return funds, rather than expansion in the scale of relative-return products. From the perspective of fund behavior, entities such as insurers and annuities do not always "invest long-term with long-term money." Quarterly and annual assessment cycles, equity position caps, solvency constraints, and drawdown stop-loss mechanisms may create passive deleveraging needs during rapid market declines, which was reflected to some extent in the market volatility in March and late September this year. By contrast, if the incremental source is expansion in new fund issuance (fund investor inflows) or large retail inflows, once the market falls rapidly, the holding period may instead be very long. This is also why this market adjustment has been faster and more intense than in the past.
In addition, most of the funds that increased equity allocations in this round followed top-down "big logic, big trend" thinking and had relatively weak stock-level pricing ability. The market easily displays "all-out attack, all-out defense" characteristics, reflected in the fact that in the A-share market, offensive varieties represented by technology and defensive varieties represented by banks are both currently at historically high valuation percentiles, while the middle section of the barbell is basically at historically extremely low valuation percentiles. Industry rotation, which remains very effective in overseas markets, is currently almost completely ineffective in A-shares; only style rotation is effective. Within industries, stocks also rise and fall together, with little differentiation among individual names. Of course, this also means that the segment easier to clear is the excellent companies in the middle section of the so-called "barbell."
The scale base of long-only quantitative products far exceeds the past, and marginal changes in scale may be very sensitive to trading volume
According to estimates by the financial products team of CITIC SEC's research department, the scale of domestic private fund quantitative equity strategies (i.e., quantitative stock selection strategies and index enhancement strategies) has continued to increase, from about RMB671.9 billion in early 2024 to about RMB1.44 trillion at the end of 2025, RMB1.95 trillion in August 2026, and the latest management scale is about RMB1.91 trillion. Quantitative strategies' breadth of stock coverage and exposure to micro- and small-cap stocks far exceed those of active products. During 2022-2023, when active products performed poorly, quantitative products generally generated positive excess returns, and their scale continued to expand, making them almost the only "easy-to-sell" products on the channel side.
This scale expansion process was also accompanied by a systemic uplift in micro- and small-cap stock valuations, allowing "stay away from institutional stocks, embrace small caps" to become an effective defensive strategy when market conditions were poor, because long-only quantitative products almost never actively reduce positions. From 2024 to now, the scale of long-only quantitative products has expanded by nearly 3x, and average daily market turnover has expanded by 3.22x (from RMB897.1 billion in 2024Q1 to RMB2.8859 trillion in 2026Q2). During this process, the Wind Micro-Cap Index cumulatively rose 74.2%, consuming a large amount of market liquidity.
However, as market turnover continues to contract (averaging only RMB1.6705 trillion per day in October-November this year), it may no longer be sufficient to support long-only quantitative products with a scale of nearly RMB2 trillion in generating overall excess returns. They will likely experience a period of persistently declining overall excess returns, product survival-of-the-fittest, and slow contraction in total scale. During this process, the micro- and small-cap style as a whole will face sustained liquidity shrinkage and valuation contraction, and the clearing process will be very long. Of course, if ineffective liquidity consumption in micro- and small-caps can gradually flow back into large-cap blue chips as it did in 2016-2017, it may boost the liquidity environment for core stocks.
The clearing speed of institutional large-cap stocks is expected to be far faster than in the past, while the slow clearing process for micro- and small-caps has just begun
Compared with historical experience, the clearing process in this round's market funding environment may differ in many ways. Based on the above analysis, the following inferences can be drawn: 1) The adjustment speed of institutional large-cap stocks in this round is very likely to be far faster than in the past, and the speed of chip clearing will also be far faster than in the past. Therefore, the market's liquidity "blood loss" will not be as prolonged as before, but may instead be short, sharp, and quick. Starting in early 2027, as the new assessment year restarts, if a final round of clearing occurs, investors can consider positioning based on relative fundamental strength logic rather than continuing to cling to chip-flow logic.
2) Looking ahead, the segment truly under sustained "blood loss" pressure is more likely to be micro- and small-caps. As the center of market turnover shifts lower, many quantitative products may be squeezed out in competition due to declining returns, creating a sustained draining effect on micro- and small-cap stocks. 3) "Avoiding institutional stocks" may be a short-term effective chip-game strategy, but its period of validity should not be very long. CITIC SEC believes that next year institutional large-cap stocks are highly likely to outperform thematic small-cap stocks, because clearing will be completed earlier.
Risk factors
Intensified frictions in China-US technology, trade, and financial areas; domestic policy intensity, implementation effects, or economic recovery falling short of expectations; overseas and domestic macro liquidity tightening more than expected; further escalation of conflicts in regions such as Russia-Ukraine and the Middle East; China's real estate inventory digestion falling short of expectations.
Related Articles

BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.

Guangdong Shenling Environmental Systems (301018.SZ) plans to participate in bidding for land use rights to meet its development needs in the liquid cooling and temperature control field.

INNOVENT BIO (01801): Sintilimab ZYBRIVO receives positive CHMP opinion recommending approval for first-line treatment of non-squamous non-small cell lung cancer
BEKE-W (02423) repurchased 422,900 shares for US$2.5 million on November 13.

Guangdong Shenling Environmental Systems (301018.SZ) plans to participate in bidding for land use rights to meet its development needs in the liquid cooling and temperature control field.

INNOVENT BIO (01801): Sintilimab ZYBRIVO receives positive CHMP opinion recommending approval for first-line treatment of non-squamous non-small cell lung cancer






